Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory marginal zone lymphoma after at least one anti-CD20-based regimen.
LAMPGEN ANALYSIS
Why it matters
The accelerated decision expands BTK inhibition to previously treated marginal zone lymphoma.
What research teams should watch
Document histologic subtype and anti-CD20 exposure and track duration of response separately from initial response.
PRIMARY RECORDS